/BCAX
BCAX Stock - Bicara Therapeutics Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$17.60-0.23%
$0.04 (-0.23%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.87
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).55
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+2.3%upside
Target: $18.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BCAX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$17.42 – $17.78
TARGET (TP)$18.00
STOP LOSS$16.19
RISK/REWARD1:0.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.87
52W High$19.75
52W Low$7.80
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-82,389,000 | $-39,889,000 | $-37,656,000 |
| Net Income | $-67,995,000 | $-51,985,000 | $-37,845,000 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-1.25 | $-1.00 | $-0.73 |
Company Overview
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
71%
Hold / Neutral
2
29%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish2 Neutral/Bearish
Price Targets
$30
Average Target
↑ 72.3% Upside
Now
$8
Low
$30
Average
$48
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | Mizuho | Initiation | Neutral | $18 |
| August 19th 2025 | Piper Sandler | Initiation | Overweight | $36 |
| May 23rd 2025 | Wells Fargo | Upgrade | Equal Weight | $8 |
| April 17th 2025 | Wells Fargo | Initiation | Underweight | $8 |
| February 6th 2025 | Wedbush | Initiation | Outperform | $31 |
| December 6th 2024 | H.C. Wainwright | Initiation | Buy | $42 |
| November 5th 2024 | Rodman & Renshaw | Initiation | Buy | $48 |
| October 8th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| October 8th 2024 | Morgan Stanley | Initiation | Overweight | $35 |
| October 8th 2024 | TD Cowen | Initiation | Buy | - |
| October 8th 2024 | Stifel | Initiation | Buy | $47 |
Earnings History & Surprises
BCAXBeat Rate
20%
Last 5 quarters
Avg Surprise
-71.6%
EPS vs Estimate
Beats / Misses
1/4
Last 12 quarters
Latest EPS
$-0.67
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
No data
Q3 24
No data
Q4 24
-247.8%
$-1.60vs$-0.46
Q1 25
-25.8%
$-0.39vs$-0.31
Q2 25
-70.0%
$-0.68vs$-0.40
Q3 25
+7.4%
$-0.50vs$-0.54
Q4 25
-21.8%
$-0.67vs$-0.55
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.72 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.55 | $-0.67 | -21.8% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.54 | $-0.50 | +7.4% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.40 | $-0.68 | -70.0% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.31 | $-0.39 | -25.8% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.46 | $-1.60 | -247.8% | ✗ MISS |
Q3 2024 | Sep 13, 2024 | — | $-0.27 | — | — |
Q2 2024 | Jun 30, 2024 | — | $-0.27 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.23 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.42 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.15 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.15 | — | — |
Latest News
Mizuho Initiates Coverage On Bicara Therapeutics with Neutral Rating, Announces Price Target of $18
➖ NeutralBenzinga•Dec 18, 2025, 09:34 AM
Reported Saturday, Bicara Therapeutics Reports 57% Confirmed Overall Response Rate With 750mg Ficerafusp Alfa Weekly Plus Pembrolizumab, Supporting Pivotal Interim Analysis
📈 PositiveBenzinga•Dec 8, 2025, 09:34 AM
Bicara Therapeutics Shares Early Trial Results Backing FDA-Supported Fast-Track Drug
📈 PositiveBenzinga•Dec 1, 2025, 12:15 PM
Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $11
➖ NeutralBenzinga•Nov 11, 2025, 02:36 PM
Bicara Therapeutics Q3 EPS $(0.67) Misses $(0.54) Estimate
📉 NegativeBenzinga•Nov 10, 2025, 12:41 PM
The FDA Has Granted Breakthrough Therapy Designation To Bicara Therapeutics' Ficerafusp Alfa In Combination With Pembrolizumab For The First Line Treatment Of Patients With Metastatic Or With Unresectable, Recurrent Head And Neck Squamous Cell Carcinoma
📈 PositiveBenzinga•Oct 13, 2025, 11:39 AM
Bicara Therapeutics Files For Mixed Shelf Offering Of Up To $400M
➖ NeutralBenzinga•Oct 3, 2025, 08:35 PM
HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $40
➖ NeutralBenzinga•Aug 22, 2025, 11:03 AM
Piper Sandler Initiates Coverage On Bicara Therapeutics with Overweight Rating, Announces Price Target of $36
📈 PositiveBenzinga•Aug 19, 2025, 11:48 AM
Bicara falls after early-stage trial data for head and neck cancer therapy
📉 NegativeSeeking Alpha•May 23, 2025, 02:29 PM•Also:
Frequently Asked Questions about BCAX
What is BCAX's current stock price?
Bicara Therapeutics Inc. Common Stock (BCAX) is currently trading at $17.60 per share. The stock has moved -0.23% today.
What is the analyst price target for BCAX?
The average analyst price target for BCAX is $18.00, based on 1 analyst.
What sector is Bicara Therapeutics Inc. Common Stock in?
Bicara Therapeutics Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BCAX's market cap?
Bicara Therapeutics Inc. Common Stock has a market capitalization of $0.96 billion, making it a small-cap company.
Does BCAX pay dividends?
No, Bicara Therapeutics Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorEYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
FTRE
Fortrea Holdings Inc.
$17.74
Mkt Cap: $1.6B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
Explore stocks similar to BCAX for comparison